PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has signed an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a Phase I-ready reversal agent for ticagrelor.

Due to its mechanism of action, ticagrelor is an oral antiplatelet with the potential to be reversed. PB2452 is an investigational, intravenous Fab antibody fragment designed to specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations.

Source: PhaseBio Pharmaceuticals